Articles by Jill Wechsler - Pharmaceutical Executive

ADVERTISEMENT

Articles by Jill Wechsler

Challenges, Changes, Commitments

The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency
Feb 1, 2011

The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency

The Building Block of Drug Discovery

Director Francis Collins sees NIH as a catalyst for translating biomedical innovations into effective therapies, but skeptics fear it's harder than it looks. It's all in the DNA of its partnerships
Feb 1, 2011

With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome?

Politics & PDUFA

Jan 1, 2011

Pharma companies will assess health reform, negotiate user fees and keep an eye on federal prosecutors in the year ahead

New Ballgame in Washington

Dec 1, 2010

Republican gains in Congress create uncertainty for health reform, drug regulation, and biomedical research

Comparisons and Costs

Nov 1, 2010

PCORI is independent and transparent and likely to alter methods for assesssing the value of new therapies

Getting Ready for Sunshine

Health reform requires detailed tracking and full disclosure of fees to docs for marketing and research
Oct 1, 2010

Health reform requires detailed tracking and full disclosure of fees to docs for marketing and research

The Testing of the Tests

Sep 1, 2010

FDA seeks to regulate genetic tests more actively, while encouraging diagnostic development

Tackling Transparency

Jul 1, 2010

Drug prices, doctor payments, and FDA regulatory decisions are candidates for expanded disclosure.

Crackdown on Counterfeits

Jun 1, 2010

FDA and industry seek to ensure drug quality in a world complicated by global outsourcing and theft.

ADVERTISEMENT

Click here